Christine Burns, PA
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,191 of the $7,050 with a category attached, or 87.8%. It is spread thinly across 37 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,046 and has fallen 53.4% since, to $953 in 2025.
Across 234 payments — averaging $30.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1K
- AstraZeneca$815
- Medtronic$450
- Novo Nordisk$425
- Amgen$353
- Mannkind Corporation$273
- plus $4K from 31 others
Across 1 payment — averaging $156.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$156
What the payments were for
- Travel & lodging$71710%
- Food & beverage$6,19188%
- Education$1422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 19 | $1,187 |
| AstraZeneca | 23 | $815 |
| Medtronic | 15 | $450 |
| Novo Nordisk | 11 | $425 |
| Amgen(2 entities) | 15 | $353 |
| Mannkind Corporation | 11 | $273 |
| Insulet Corporation | 8 | $262 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $257 |
| Bayer | 13 | $246 |
| Sanofi-aventis U.S. LLC | 4 | $233 |
| Corcept Therapeutics | 4 | $232 |
| Regeneron Healthcare Solutions, Inc. | 16 | $206 |
| Ascendis Pharma Endocrinology Inc | 2 | $182 |
| Sanofi | 7 | $180 |
| GSK | 7 | $176 |
| Dexcom, Inc. | 2 | $172 |
| Abbott | 9 | $165 |
| Lilly USA, LLC | 6 | $155 |
| Calliditas Therapeutics US Inc. | 7 | $131 |
| Tandem Diabetes Care, Inc. | 1 | $117 |
| Aurinia Pharma U.S., Inc. | 5 | $108 |
| GRT US Holding, Inc. | 1 | $107 |
| Otsuka America Pharmaceutical, Inc. | 4 | $106 |
| Fresenius USA Marketing, Inc. | 4 | $69 |
| Boehringer Ingelheim | 3 | $65 |
| Recordati_rare_diseases_inc. | 3 | $58 |
| Mylan Specialty L.p. | 3 | $57 |
| Radius Health, Inc. | 3 | $43 |
| Biocryst US Sales Co., LLC | 2 | $37 |
| Travere Therapeutics, Inc. | 2 | $35 |
| Novartis | 1 | $29 |
| Optinose US, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Abiomed | 1 | $22 |
| Ardelyx, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$233
- DEXCOM G6 TRANSMITTER$150
- Korlym$138
- Omnipod$130
- t:slim X2 Insulin Pump with Control-IQ$117
- AIRSUPRA$112
- Saxenda$111
- EVENITY$110
- Qutenza$107
- TZIELD$107
How this compares
$7,050 in reported general payments places this provider in the 85th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $179,396 |
| MounjaroTirzepatide | 109 | $153,385 |
| JardianceEmpagliflozin | 98 | $125,227 |
| TrulicityDulaglutide | 85 | $98,294 |
| TymlosAbaloparatide | 20 | $97,346 |
| FarxigaDapagliflozin Propanediol | 54 | $63,072 |
| RybelsusSemaglutide | 35 | $52,076 |
| ForteoTeriparatide | 12 | $50,551 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $45,077 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $24,680 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $19,064 |
| Humalog Kwikpen U-100Insulin Lispro | 35 | $11,591 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $11,000 |
| NovologInsulin Aspart | 31 | $10,030 |
| Novolog FlexpenInsulin Aspart | 49 | $9,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $155 | $308,145217 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $425 | $241,501175 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $65 | $149,907115 claims |
| Radius Health, Inc.Tymlos | $43 | $97,34620 claims |
| AstraZenecaFarxiga | $815 | $63,07254 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $233 | $11,00013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 medical providers in Nevada.
Other medical in Reno
- Ashley OwensReno$7K
- Brian DouglasReno$7K
- Sarah GutierrezReno$6K
- Bradley BusReno$6K
- Melissa ShelleyReno$6K
- Gretchen GoicoecheaReno$5K
- Nicholas BeaudetteReno$4K
- Shaylee NystromReno$4K
- Sheila QuinnReno$4K
- Carla ChongReno$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.